SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-011766
Filing Date
2024-03-06
Accepted
2024-03-06 17:13:04
Documents
19
Period of Report
2024-03-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20019103x3_8k.htm   iXBRL 8-K 31507
2 EXHIBIT 1.1 ny20019103x3_ex1-1.htm EX-1.1 201782
3 EXHIBIT 5.1 ny20019103x3_ex5-1.htm EX-5.1 8895
4 EXHIBIT 99.1 ny20019103x3_ex99-1.htm EX-99.1 9496
5 EXHIBIT 99.2 ny20019103x3_ex99-2.htm EX-99.2 9573
9 ny20019103x3_ex5-1img01.jpg GRAPHIC 4542
  Complete submission text file 0001140361-24-011766.txt   466228

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA bbio-20240305.xsd EX-101.SCH 3868
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20240305_lab.xml EX-101.LAB 21966
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20240305_pre.xml EX-101.PRE 16046
21 EXTRACTED XBRL INSTANCE DOCUMENT ny20019103x3_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 24726988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)